Drug Database
ES

estrogens (Cenestin / Bijuva, Barr)

✓ Approved

Teva Pharmaceutical Industries Ltd. · ESR1

What is estrogens?

estrogens is a therapeutic agent developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via intravaginal or oral (po).

Drug Profile

Brand NamesCenestin, Bijuva, Barr
CompanyTeva Pharmaceutical Industries Ltd.
Molecular TargetESR1
RouteIntravaginal, Oral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

estrogens acts on 1 molecular target:

ESR1estrogen receptor 1 (ER, ESR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

estrogens is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersAtrophic vulvovaginitis✓ Approved
Surgical and medical proceduresHormone replacement therapy✓ Approved
Reproductive system and breast disordersMenopausal symptoms✓ Approved

Related Research Articles

PubMedJournal of clinical and experimental hematopathology : JCEH2026-08-30

Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

Ichikawa Satoshi S, Suzuki Yutaka Y, Tanaka Yuya Y, Kanba Keita K et al.

Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein-Barr virus (EBV) infection, particularly in the mixed-cellularity and lymphocyte-depleted subtypes. No consensus has been reached regarding treatment for HL-HLH, and the myelotoxicity induced by etoposide-based HLH-directed therapy precludes its safe addition to intensive lymphoma-directed chemotherapy, particularly in older patients. We here report the case of a male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma (CHL) who presented with cervical lymphadenopathy, fever, hepatosplenomegaly, and a markedly elevated soluble interleukin-2 receptor (sIL-2R) level, along with a high peripheral blood EBV DNA load. EBV-encoded small RNA in situ hybridization confirmed EBV positivity in lymphoma cells. His fever was steroid-refractory, and chemotherapy with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) was initiated immediately following the diagnosis was confirmed. However, the persistent high fever did not resolve, and progressive cytopenia, marked hyperferritinemia, and further increase in sIL-2R levels were observed. Repeat bone marrow examinations revealed macrophage activation with hemophagocytosis, confirming HLH as a complication. Rituximab was promptly administered, and the fever resolved within 3 days. Furthermore, ferritin, sIL-2R, and lactate dehydrogenase levels substantially declined within 1 week, with peripheral blood EBV DNA becoming undetectable. BV-AVD was continued without major complications and led to a complete response after six cycles. Rituximab may represent a strategically timed and reasonable adjunctive intervention for EBV-driven HL-HLH that is refractory to, or develops following, chemotherapy for CHL.

PMID 42669549
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

Hyper-Intense Tumor Peripheral Accumulation of Antibody-Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging.

Korangath Preethi P, Carlton Hayden H, Wong Theresa T, Healy Sean S et al.

Targeting nanoparticles to cancer cells in vivo remains a challenge for cancer imaging. We assessed nanoparticle distribution after injecting iron oxide nanoparticles conjugated with either a monoclonal anti-HER2 (human epidermal growth factor 2), or a non-specific IgG antibody into a human HER2 overexpressing murine breast cancer model. We used Magnetic Particle Imaging (MPI) and histopathology to assess particle localization at 72 h after injection. MPI detects magnetic moments produced by magnetic particles, and histology enables spatial quantification of nanoparticles. Intratumor iron content measured by MPI correlated with inductively coupled plasma mass spectrometry (ρ = 0.868, p < 0.0001). We detected nanoparticle accumulation in tumors, and organs and tissues associated with inflammation. MPI showed higher uptake of nanoparticles in tumors, regardless of their performance in vitro. Spatial analysis showed that 43 ± 7% of nanoparticles that reached the tumor accumulated in the peripheral quartile of the tumor, with decreasing amounts toward the center. Immunohistochemical analysis showed the nanoparticles were strongly associated with inflammatory immune and stromal cells in the tumor microenvironment. This hyperintense peripheral accumulation, or ring pattern, observed with MPI enabled us to distinguish tumors from general inflammation. Iron oxide nanoparticle-mediated MPI has the potential to detect tumors, providing another powerful diagnostic tool.

PMID 42669153
Read full article →
PubMedTransplantation reviews (Orlando, Fla.)2026-08-30

Malignancy after lung transplantation: Understanding risk and navigating treatment.

Yang Haoshuai H, Yang Zhanglin Z, Xu Kai K, Chen Qi Q et al.

Malignancy has become a major limitation to long-term survival after lung transplantation. Its risk is shaped by recipient susceptibility, transplant anatomy, oncogenic viruses, long-term immunosuppression, and drug exposure. This narrative review integrates epidemiological, mechanistic, and clinical evidence and proposes a management framework spanning pre-transplant assessment, post-transplant surveillance, and treatment after cancer diagnosis. Lung cancer arises predominantly in the retained native lung after single-lung transplantation; early detection and curative treatment are central to improving outcomes. Keratinocyte carcinoma is common and recurrent, requiring coordinated dermatological surveillance, preventive treatment, and review of relevant drug exposures. Post-transplant lymphoproliferative disorder (PTLD) is closely linked to impaired Epstein-Barr virus (EBV) immune control. High-risk recipients warrant longitudinal viral monitoring, but diagnosis still requires histopathology, and treatment is based on reduced immunosuppression and response-adapted rituximab-based strategies. After cancer diagnosis, immunosuppression should be reconfigured according to tumour lethality, allograft reserve, and rejection risk, while coordinating anticancer therapy with allograft protection. Biomarkers may support monitoring, antibody-drug conjugates may expand treatment options, and immune checkpoint inhibitors may cause fatal allograft injury. Future work should use prospective registries and auditable pathways to evaluate cancer control and allograft outcomes together.

PMID 42669217
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects].

Fujimoto Ayumi A

Mature NK/T-cell lymphomas are a rare group of lymphoma subtypes, represented by extranodal NK/T-cell lymphoma (ENKL) and aggressive NK-cell leukemia (ANKL). Both subtypes are strongly associated with Epstein-Barr virus and show a high prevalence, particularly in East Asia and Central and South America. In Japan, ENKL currently accounts for approximately 1% of all malignant lymphomas, whereas ANKL is even rarer, accounting for approximately 0.1%. ENKL and ANKL share many clinical and pathological features. However, as evidence regarding differences in molecular biological characteristics, including genetic and chromosomal abnormalities, has gradually accumulated, they have been recognized as distinct disease entities since the 2001 WHO classification (3rd edition). Since the 2000s, the treatment of ENKL has markedly advanced with the development of non-anthracycline-based regimens. In Japan, RT-2/3DeVIC for localized-stage ENKL and SMILE for stage IV and relapsed/refractory ENKL were developed and remain the current standard of care. In contrast, because ANKL is a rare disease and reports on its treatment are limited, it is usually treated using strategies for advanced-stage ENKL. This review focuses on ENKL and ANKL, providing an overview of their disease characteristics, evolving treatment and prognosis, and future challenges and perspectives.

PMID 42669517
Read full article →
PubMedACS chemical biology2026-08-30

Democratizing LYTACs-A Modular Click Chemistry Platform for the Rapid Assembly of Lysosome-Targeting Chimeras.

Szijj Peter A PA, Li Sherry S, Gilbert Madeline K MK, Rollock Chloë Wood CW et al.

Lysosome-targeting chimeras (LYTACs) are emerging therapeutics that mediate extracellular targeted protein degradation. Through simultaneous engagement of a target protein of interest and a lysosomal trafficking receptor, these bifunctional molecules can facilitate the degradation of both secreted and cell-surface proteins. The original LYTACs were designed to engage the cation-independent mannose-6-phosphate receptor (CI-M6PR) via complex glycopolymer or glycopolypeptide ligands conjugated to target-specific antibodies. However, the complexity of these ligands has limited the broader adoption of LYTACs as research tools. Here, we describe a simple, rapid, and modular click chemistry platform for the generation of CI-M6PR-binding LYTACs. The approach utilizes only commercially available reagents and standard laboratory equipment and allows for the conversion of virtually any antibody into a LYTAC. This method for "democratizing" LYTAC generation should facilitate the widespread adoption of these tools for biological discovery.

PMID 42669291
Read full article →
PubMedCureus2026-08-30

Acute EBV-Associated Systemic Inflammatory Syndrome Presenting as PUO With FDG-Avid Generalized Lymphadenopathy, Autoimmune Serological Positivity and Myopericarditis Mimicking Lymphoma and Connective Tissue Disease: A Diagnostic Challenge.

Abbasi Abdul Haleem AH, Job Mridhu M, Faiza Fahmida F, Rahman Ameena A et al.

Pyrexia of unknown origin (PUO) remains a diagnostic challenge, particularly when associated with lymphadenopathy, multisystem involvement and positive autoimmune serology. Distinguishing between infectious, inflammatory and malignant causes is often difficult, especially when advanced imaging demonstrates findings suggestive of lymphoma. A previously healthy man in his late 40s presented with a 10-day history of intermittent fever, myalgia, joint stiffness and pleuritic chest pain. During admission, he developed photophobia, mild neck stiffness, progressive upper and lower limb pain and weakness resulting in impaired mobility. Investigations demonstrated marked systemic inflammation with a C-reactive protein (CRP) of 235 mg/L and an erythrocyte sedimentation rate (ESR) of 105 mm/hr despite a normal white cell count (WCC). Extensive microbiological investigations including blood cultures, cerebrospinal fluid analysis, bacterial and fungal molecular testing, tuberculosis screening and viral polymerase chain reaction (PCR) testing were negative apart from detectable Epstein-Barr virus (EBV) DNA and positive EBV IgM serology. Autoimmune screening revealed positive ANA, anti-Ro52, anti-Ro60 and anti-La antibodies with low complement C4. Cardiac magnetic resonance imaging (MRI) confirmed acute myopericarditis. Positron emission tomography-computed tomography (PET-CT) demonstrated fluorodeoxyglucose (FDG)-avid supra- and infradiaphragmatic lymphadenopathy with splenic involvement highly suspicious for lymphoma. However, excisional cervical lymph node biopsy demonstrated reactive lymphoid hyperplasia without evidence of malignancy. Clinical improvement began approximately during the second week after admission and occurred without immunosuppressive therapy.

PMID 42669013
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about estrogens